Synthetica Pioneering Completes Series A Funding Round to Advance Oncolytic Bacterial Treatment

Synthetica Pioneering Completes Series A Funding Round to Advance Oncolytic Bacterial Treatment for Solid Tumors

Overview

Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup focused on synthetic biology for creating novel bacterial therapeutics, has recently completed a Series A funding round. The investment was led by Boehringer Ingelheim Venture Fund and Temasek, with additional contributions from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund. The funds will be used to expedite the clinical trials of Synthetica's oncolytic bacterial therapies.

About Synthetica

• Established in 2023 and based in Shenzhen, China, Synthetica specializes in genetic circuit engineering to precisely control genes and payloads for therapeutic purposes. 
• The company is currently concentrating on developing oncolytic bacterial therapies for the treatment of solid tumors. 
• With advanced synthetic biology techniques and a strong grasp of biological mechanisms, Synthetica aims to create innovative, safe, and minimally invasive treatments for cancer.

Words from CEO: Synthetica

Synthetica’s CEO, Yingke He, expressed, “This funding represents a crucial development for our company as we advance cancer treatment. Our approach to synthetic biology and oncolytic bacteria provides new possibilities for targeted therapies. We appreciate the support from our technology partners and investors, and we are committed to making significant progress in cancer treatment to improve patients' lives worldwide.”

From the Boehringer Ingelheim Venture Fund

• Dr. Mia Hu, Investment Director at Boehringer Ingelheim Venture Fund, noted, “Boehringer Ingelheim Venture Fund is dedicated to supporting innovative therapeutics that address significant patient needs.” 
• Oncolytic bacterial therapy is a strategic priority for us, and we are excited to back Synthetica. Their expertise in synthetic biology and the development of bacterial therapies is promising, and we are eager to see their impact on treating solid tumors and enhancing patient outcomes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!